IN THE CLAIMS:

1. (Currently Amended) A method for treating an Aspergillus infection in a mammal ~~or preventing an Aspergillus infection in an immunocompromised host~~ comprising administering to said mammal a pharmaceutical composition comprising an antifungal effective amount of thymosin alpha 1 (TA1).

2. (Original) The method according to claim 1, wherein said TA1 is administered at a dose sufficient to activate dendritic cells to produce Th1 cell promoting cytokines.

3. (Original) The method according to claim 1, wherein said TA1 is administered at a dose of 200 to 400 micrograms/kg body weight/day.

4. (Currently amended) The method according to claim 1, wherein said mammal is ~~an~~ immunocompromised ~~immuno-compromised host~~.

5. (Original) The method according to claim 4, wherein said mammal is a human.

6. (Original) The method according to claim 5, wherein said human is a bone marrow transplantation recipient.

7. (Original) The method according to claim 5, wherein said TA1 is administered to activate dendritic cells to produce Th1 cell promoting cytokines.

8. (Original) The method according to claim 5, wherein said TA1 is administered at a dose of 200 to 400 micrograms/kg body weight/day.

9. (Currently amended) The method according to claim 1, wherein the method further comprises administering to said mammal ~~person~~ at least one additional antifungal agent.

10. (Original) The method according to claim 9, wherein the additional antifungal agent is Amphotericin B.

11. (Original) The method according to claim 10, wherein said Amphotericin B is administered at a dose of 4000 micrograms/kg body weight/day.

12. (Original) The method of claim 1 wherein said Aspergillus infection is Invasive Aspergillosis.